In vitro metabolism of FK-506 in rat, rabbit, and human liver microsomes: identification of a major metabolite and of cytochrome P450 3A as the major enzymes responsible for its metabolism
- PMID: 1373595
- DOI: 10.1016/0003-9861(92)90711-5
In vitro metabolism of FK-506 in rat, rabbit, and human liver microsomes: identification of a major metabolite and of cytochrome P450 3A as the major enzymes responsible for its metabolism
Abstract
The metabolism of the immunosuppressant FK-506 was shown to be catalyzed primarily by cytochrome P450 isozymes of the P450 3A subfamily. Antibodies against rat P450 3A inhibited FK-506 metabolism by 82% in rat liver microsomes and by 35-56% in liver microsomes from humans, dexamethasone-induced rats, and erythromycin-induced rabbits. Poor species cross-reactivity of the antibodies, metabolic switching, and/or some metabolism by P450 isozymes other than P450 3A may be responsible for the incomplete inhibition observed. Besides anti-rat P450 3A, antibodies against rat P450 1A also appeared to have some inhibitory effect implicating these particular cytochrome P450 isozymes as having a minor role in FK-506 metabolism. The formation of 13-desmethyl FK-506, identified here as a major metabolite of FK-506 in all types of microsomes examined, was inhibited completely by anti-P450 3A in liver microsomes from dexamethasone-induced rats and erythromycin-induced rabbits but only partially in human and control rat liver microsomes.
Similar articles
-
Metabolism of FK506, a potent immunosuppressive agent, by cytochrome P450 3A enzymes in rat, dog and human liver microsomes.Biochem Pharmacol. 1994 Feb 11;47(4):727-35. doi: 10.1016/0006-2952(94)90136-8. Biochem Pharmacol. 1994. PMID: 7510480
-
Involvement of human liver cytochrome P450 3A in vinblastine metabolism: drug interactions.Cancer Res. 1993 Nov 1;53(21):5121-6. Cancer Res. 1993. PMID: 8221648
-
Human liver microsomal cytochrome P450 3A isozymes mediated vindesine biotransformation. Metabolic drug interactions.Biochem Pharmacol. 1993 Feb 24;45(4):853-61. doi: 10.1016/0006-2952(93)90169-w. Biochem Pharmacol. 1993. PMID: 8452560
-
Recent advances in the metabolism of cannabinoids.Int J Biochem Cell Biol. 1995 Aug;27(8):741-6. doi: 10.1016/1357-2725(95)00043-o. Int J Biochem Cell Biol. 1995. PMID: 7584607 Review.
-
Alternative cyclosporine metabolic pathways and toxicity.Clin Biochem. 1995 Dec;28(6):547-59. doi: 10.1016/0009-9120(95)00037-3. Clin Biochem. 1995. PMID: 8595701 Review.
Cited by
-
Mechanisms of clinically relevant drug interactions associated with tacrolimus.Clin Pharmacokinet. 2002;41(11):813-51. doi: 10.2165/00003088-200241110-00003. Clin Pharmacokinet. 2002. PMID: 12190331 Review.
-
Donor CYP3A5 Gene Polymorphism Alone Cannot Predict Tacrolimus Intrarenal Concentration in Renal Transplant Recipients.Int J Mol Sci. 2020 Apr 23;21(8):2976. doi: 10.3390/ijms21082976. Int J Mol Sci. 2020. PMID: 32340188 Free PMC article.
-
Personalization of the immunosuppressive treatment in renal transplant recipients: the great challenge in "omics" medicine.Int J Mol Sci. 2015 Feb 17;16(2):4281-305. doi: 10.3390/ijms16024281. Int J Mol Sci. 2015. PMID: 25690039 Free PMC article. Review.
-
Clinical Evaluation of Modified Release and Immediate Release Tacrolimus Formulations.AAPS J. 2017 Sep;19(5):1332-1347. doi: 10.1208/s12248-017-0119-z. Epub 2017 Jul 17. AAPS J. 2017. PMID: 28717926 Review.
-
Voriconazole inhibition of the metabolism of tacrolimus in a liver transplant recipient and in human liver microsomes.Antimicrob Agents Chemother. 2002 Sep;46(9):3091-3. doi: 10.1128/AAC.46.9.3091-3093.2002. Antimicrob Agents Chemother. 2002. PMID: 12183280 Free PMC article. Clinical Trial.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources